Podcast Summary

Podcast: Plain English with Derek Thompson
Episode: The Future of GLP-1 Drugs and AI Medicine, With Eli Lilly CEO David Ricks
Date: February 24, 2026
Guest: David Ricks, CEO of Eli Lilly

Overview

This episode delves into the GLP-1 drug revolution, its origins, far-reaching implications, and future directions. Derek Thompson interviews Eli Lilly CEO David Ricks about the science, business, and societal impact of GLP-1 drugs (like Mounjaro/Zepbound), the pharmaceutical innovation landscape, and how artificial intelligence might speed up medical breakthroughs. They discuss how these drugs emerged, their surprising effects beyond weight loss, challenges in adherence and cost, the public’s distrust of “Big Pharma,” and the long-term promise and limits of AI in drug discovery.

Key Discussion Points and Insights

1. Origins & Development of GLP-1 Drugs

[06:16 – 13:15]

• Historical Context:
  • The story of GLP-1 drugs starts in the 1970s with the discovery of the incretin effect—where hormones from the gut (incretins) regulate how the body processes food.
  • Early breakthroughs identified gut hormones like GIP and GLP-1 that signal satiety and glucose uptake.
  • The Gila monster’s peptide (exendin) paved the way for the first human drugs by providing longer-lasting effects—a foundational discovery for drugs like exenatide (Byetta).
  • Initially, these drugs were used to treat type 2 diabetes, with weight loss observed as a secondary effect.

"The effect is really sort of the insight into the natural system by which we regulate calories, which is kind of core to our existence." — David Ricks (08:24)

• Improvement Cycle:
  • Incremental advances in peptide chemistry led to weekly drugs (Trulicity/Ozempic), making dosing easier and side effects less severe.
  • Dual and now triple agonists (e.g., tirzepatide and retatrutide) aim to increase efficacy and convenience.

2. GLP-1: From Diabetes to Weight Loss and Beyond

[13:52 – 24:29]

• Metabolic and Broader Benefits:
  • GLP-1 drugs’ core effect is enhancing satiety and facilitating weight loss.
  • Expanded benefits include lowering the risk of heart disease, improving insulin sensitivity, reducing inflammation, and even decreasing the prevalence of some cancers.
  • Early studies show potential in treating addictions (smoking, alcohol), joint pain (osteoarthritis), and possibly neurological disorders.

“We have a study where we watch people on tirzepatide for three years and they had 92% less diabetes at the end of the study.” — David Ricks (15:54)

• Suppressing Addictive Behaviors:
  • Drugs show secondary effects on dopamine-driven behaviors, decreasing impulses for not just food but also substances and possibly habits like shopping or gambling.

“We also report less online shopping and less gambling while on these drugs, which I think wasn’t the initial — no one would have hypothesized that at the beginning.” — David Ricks (19:26)

3. Adherence Issues and the Challenge of Discontinuation

[24:29 – 29:12]

• Adherence Rates:
  • Over half of patients discontinue GLP-1 drugs within two years—a pattern similar to other chronic medications.
  • Discontinuation is mainly due to life events, cost, supply issues, or side effects (more acutely at higher doses).
• Weight Loss Reversal:
  • Stopping the medication results in weight regain and loss of associated benefits.

“Most of the health gains will reverse pretty quickly for most people…we’re not curing anything here.” — David Ricks (27:30)

• Public Service Note:
  • Ricks emphasizes consulting healthcare professionals before starting these drugs given side effect profiles and the risks of “bypassed” online access.

4. Pipeline & Future Directions for GLP-1 Drugs

[29:12 – 34:33]

• Key Axes of Progress:

  1. Boosting Weight Loss:
     • Triple agonists (like retatrutide) show promise for 28-30% weight loss—comparable to surgical interventions.
  2. Reducing Side Effects:
     • Development of new molecules (like alurolentide, an amylin-based drug) that offer substantial weight loss with minimal GI side effects.
  3. Alternative Indications:
     • Potential to treat inflammation (e.g., asthma), addiction (alcohol, tobacco), or even neuropsychiatric disorders.

• Convenience Innovations:

  • Oral versions, longer-acting injectables (quarterly, maybe even yearly), and drugs targeting specific comorbidities are all in development.

5. The Pharmaceutical Business Model Explained

[36:51 – 47:21]

• R&D Cycle:
  • The business hinges on government-granted patents (about 10 years after R&D), after which profit “evaporates.”
  • Around 20% of revenue is reinvested into R&D—the majority funding clinical trials (i.e., “we have 365,000 people in a Lilly clinical trial”).
  • Failed trials are factored into drug pricing—R&D costs include both successful and unsuccessful bets.

“You have this melting iceberg problem…eventually it’ll become nothing and the company needs to recoup its investment.” — David Ricks (42:15)

• Role Relative to NIH:
  • NIH supports frontier basic research (e.g., studying Gila monster saliva); pharma companies focus on turning scientific insights into scalable, patent-protected products.

6. How to Optimize R&D and the Role of Taste, Efficiency, and Franchising

[47:21 – 55:24]

• Secrets to Picking Winners:
  1. Stability & Domain Expertise:
     • Stick to core disease areas and keep key scientific talent.
  2. Shorten Cycle Times:
     • Invest in R&D and production in parallel ("pre-invest"), accepting some waste for speed gains.
  3. Leverage Hits:
     • Successfully mine a biological insight (like GLP-1s): use “franchise” thinking to create a series of related, improving drugs.
• Platform Analogy:
  • Like an entertainment franchise, breakthroughs can spawn “sequels” with iterative improvements (but each must beat generics to succeed).

“Once something’s hot, you’re almost too late to jump into that space. The cycle time’s too slow in our industry.” — David Ricks (51:02)

7. Why Does America Distrust Pharma?

[55:24 – 63:53]

• Gallup Data:
  • The pharmaceutical industry consistently ranks lowest in public esteem, even beneath the federal government.
• Ricks’ Diagnosis:
  1. Complexity:
     • R&D timelines are long and hard to communicate.
  2. Necessity & Dependency:
     • Nobody resents buying a phone, but they resent being forced to buy lifesaving drugs.
  3. Out-of-Pocket Costs:
     • Insurance shields patients from most health services’ costs, but not drug costs—drugs are 9% of healthcare but “feel” much more expensive.

“We make products that people feel like they don’t have a choice to purchase. And I think industries that have that dimension are almost universally disliked.” — David Ricks (57:30)

• Cost Structure Challenge:
  • Patent medicine economics create inherent tension: high prices are set precisely when drugs are in highest demand, before generics arrive.

8. Why Drug Development is So Expensive in the U.S.

[61:01 – 63:53]

• Regulatory Load:
  • Regulation is additive—each new requirement never disappears.
• Scientific Hurdles:
  • Every new drug must outperform cheap, effective generics.
• Technology Escalation:
  • Each improvement layer (e.g., personalized therapies like CAR-T) increases cost, though may drop as tech matures.

9. The Reality and Limitations of AI in Medicine

[63:53 – 68:24]

• Promise and Pitfalls:
  • General AI (e.g., LLMs like ChatGPT) aren’t equipped for deep biology; they lack specialized training data and understanding.
  • Narrow AI tools (e.g., AlphaFold for protein folding) work well for specific problems but don’t generalize across biological systems.
  • Progress needs a vast new “internet” of biological knowledge—a corpus of high-fidelity, well-tagged biological data to create useful models.
  • Real progress may be decades away, though ongoing investments (partnerships with Nvidia, dedicated supercomputing) aim to accelerate timelines.

“The language models don’t translate to biology. We need a new language, and we need to train it on that. Unfortunately, we don’t speak the language of biology that well. We’re sort of like a toddler in the language of biology.” — David Ricks (68:24)

Notable Quotes

• “We’re boosting [hormones] to a super normal level and it suppresses appetite, kicks in the metabolism, et cetera…to do that, you need to get to higher levels than we were originally to see the weight loss effects.” — David Ricks (10:53)

• “What seems to be magical here, really quite unique in this pathway, is we do tend to suppress these kind of urges without inducing depression or other things that change brain chemistry in a way that’s quite negative.” — David Ricks (22:12)

• “It wasn’t too long ago, Derek, in 2017, if you said, hey, we’re spending a lot of money on an obesity drug, our investors would have looked at us like we were crazy…Once something’s hot, you’re almost too late to jump into that space.” — David Ricks (51:00)

Timestamps by Segment

• GLP-1 Drug Origins & Science — [06:16 – 13:15]
• GLP-1 Expanding Benefits & Mechanism Mysteries — [13:52 – 24:29]
• Adherence Problem and Access Issues — [24:29 – 29:12]
• Future Directions: Triple Agonists and New APIs — [29:12 – 34:33]
• Pharma Business 101: Patents, R&D, and the Melting Iceberg — [36:51 – 47:21]
• Picking Winners, Speed, and Franchise Innovation — [47:21 – 55:24]
• Distrust & Cost: Why America Hates Pharma — [55:24 – 63:53]
• Regulatory & Scientific Barriers to Cheaper Drugs — [61:01 – 63:53]
• AI in Drug Development: Hype vs. Reality — [63:53 – 68:24]

Memorable Moments

• GLP-1 drugs as “a system-wide mechanism for increasing moderation”:
  Thompson’s philosophical musing on how these increasingly affect not just food intake but broad behavioral impulses.

“Spookiest about this…these drugs almost act as a system wide mechanism for increasing moderation…” (20:53)

• Ricks’ candor about public perception:

“We make products that people feel like they don’t have a choice to purchase…industries that have that dimension are almost universally disliked…” (57:30)

• AI’s slow revolution in drug discovery:

“We don’t speak the language of biology that well. We’re sort of like a toddler in the language of biology.” (68:24)

Summary Takeaway

GLP-1 drugs’ emergence embodies both serendipity and scientific perseverance, offering unexpected benefits for obesity and an array of chronic problems. While the pharmaceutical engine is slow, expensive, and often distrusted, Ricks argues that platforms like Lilly accelerate progress by both strategic focus and serial innovation—with AI promising but not yet realizing its transformative potential. The episode provides rare, plain-English clarity about how drug revolutions happen (and why they’re so costly and slow), why pharma is “hated,” and how medical breakthroughs might come faster in the future—if we can solve the fundamental “language” of biology.